nonprofit logo

Advancing Cancer Treatment

Learn about this cause: What are the reviews? Is it Legit? Do I like the mission? What is the CEO's salary?

EIN: 832886283 ✦ Moultonborough, NH ✦ Designated as a 501(c)(3)

Shop smarter and support your favorite cause at the same time! With the Give Freely browser extension, you'll automatically save money with coupons, and partner stores will donate to your chosen charity - at no extra cost to you. Start giving back with a single click. It's safe, free, and spam-free, guaranteed!

Overview

What is Advancing Cancer Treatment?

Advancing Cancer Treatment (ACT) is a nonprofit organization situated in Moultonborough, New Hampshire. Their primary focus is on enhancing participant enrollment in prostate cancer clinical trials. ACT aims to establish a registry, encouraging a substantial number of prostate cancer patients to participate by submitting a straightforward saliva test, which provides their genetic information for research purposes. This registry would also provide an alert service, notifying them if any treatments or therapies match their profile, potentially improving their prognosis. ACT's mission is to transform the Washington, D.C. metropolitan area into a pioneer in boosting clinical trial enrollment, thereby expediting improved cancer care and treatment.


Official website here: www.actclinicaltrials.org

What are the reviews and ratings of this charity?

Charity Navigator Rating: 93% (Four-Star out of Four Stars)

Advancing Cancer Treatment has achieved a Four-Star rating from Charity Navigator, reflecting its strong performance in accountability and finance. The organization's score is derived entirely from a robust accountability and finance rating, indicating a high level of transparency and effective management of resources. The majority of the board members are independent, enhancing governance and oversight.

The nonprofit excels in several key financial metrics, including a program expense ratio of 97.74%, signifying that a significant portion of its funding is directed towards its mission rather than administrative costs. Its fundraising efficiency ratio stands at $0.00, suggesting that the organization does not incur expenses in fundraising efforts, which is a positive indicator of operational efficiency.

While the organization performs well overall, it has a working capital ratio of 0.35 years, which may raise concerns about its short-term financial sustainability. However, the lack of material asset diversion, loans to officers, and a strong audit committee contributes to its compelling accountability profile. Overall, Advancing Cancer Treatment demonstrates a commitment to effective financial stewardship and transparency.


This AI summary has been generated from information found on Charity Navigator.

Is Advancing Cancer Treatment legitimate?

Advancing Cancer Treatment is a legitimate nonprofit organization registered as a 501(c)(3) entity. Advancing Cancer Treatment submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.


Heare are some key statistics you may want to consider:

Executive Compensation: $0
Professional Fundraising Fees: $0
Other Salaries and Wages: $0

For more financial information, click here


Official website here: www.actclinicaltrials.org

What is the mission statement of Advancing Cancer Treatment?

Advancing Cancer Treatment (ACT) aims to lead the way in accelerating improved cancer care and treatment by increasing participation in clinical trials in the broader cancer research community. Currently, their focus is on prostate cancer clinical trials, with an objective to create a prostate registry. This registry aims to enroll a significant portion of prostate cancer patients by having them submit a simple saliva test for genetic information, which can be used in research. Additionally, ACT offers an alert service to these patients, notifying them if any treatments or therapies matching their genetic profile become available, potentially improving their outcomes.


Official website here: www.actclinicaltrials.org

Who is the CEO of Advancing Cancer Treatment?

Pamela Brown is the Director of Advancing Cancer Treatment.


Official website here: www.actclinicaltrials.org

What is the revenue of Advancing Cancer Treatment?

Advancing Cancer Treatment's revenue in 2022 was $3,010,183.


Official website here: www.actclinicaltrials.org

Who are the executives of Advancing Cancer Treatment and what are their salaries?

There 7 volunteers at Advancing Cancer Treatment.


Here are 7 key members and their salaries:


Otis Brawley (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Robert Grossman (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Jenny B Aragon-Ching Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Donald L Trump Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Adam R Metwalli Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Pamela Brown (Vice President, Secretary)
  • Compensation: $0
  • Related: $0
  • Other: $0
David Brown (President, Treasurer)
  • Compensation: $0
  • Related: $0
  • Other: $0


Official website here: www.actclinicaltrials.org

Where can I find the form 990 for Advancing Cancer Treatment?

Advancing Cancer Treatment's most recent form 990 was submitted in 2022 and can be accessed here.


Official website here: www.actclinicaltrials.org

Learn more at the official website: www.actclinicaltrials.org

Mission Statement of Advancing Cancer Treatment

Advancing Cancer Treatment (ACT) is committed to driving innovation in cancer care and treatment in the field of clinical trials. Their mission is to position the Washington, D.C. metropolitan area as a leading hub for accelerating improved cancer treatment through enhanced clinical trial enrollment. ACT's primary goal is to advance cancer care by making significant strides in prostate cancer clinical trials. To achieve this, ACT is establishing a prostate registry, aiming to encourage a substantial portion of prostate cancer patients to participate. This participation is facilitated by a simple saliva test, which collects genetic information for research purposes. Additionally, ACT provides an alert service to patients, notifying them if any treatments or therapies that align with their genetic profile become available, potentially improving their outcome.

Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!

Impact




July, 2024

Advancing Cancer Treatment's impact lies in its mission to make the Washington, DC metropolitan area a leader in advancing clinical trial accrual for improved cancer care and treatment. By focusing on improving accrual to prostate cancer clinical trials, ACT aims to create a prostate registry that encourages a significant portion of patients to participate by submitting a simple saliva test for their genetic information. This initiative not only facilitates research but also provides an alert service to patients if any treatments or therapies match their profile, potentially changing their outcome. Through these efforts, Advancing Cancer Treatment is actively working towards enhancing cancer treatment options and outcomes in the region.




This information is meant to be a general summary of Advancing Cancer Treatment. Please take the time to review official sources before making any decisions based upon the content provided here.


Financials

This financial information is from Propublica.

Revenue
$3,010,183 (2022)
Expenses
$3,103,502 (2022)
Efficiency

Other financial information:

This information is from the most recently submitted tax form from this organization, which was in 2022.

  • Investment Income: $10,183
  • Gross Receipts: $3,010,183

Assets and Liabilities:

  • Total Assets: $683,975
  • Total Liabilities: $37,428
  • Net Assets: $646,547

Want to help this charity, for free? You can click here to learn more about Give Freely

Organization Details

Founding Year

2018

Principal Officer

Pamela Brown

Main Address

42 RUPPERT RD, MOULTONBOROUGH, NH, 03254

NTEE Category

Code: G12 - Disease

If you are a representative of Advancing Cancer Treatment and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.